Latest From KemPharm Inc.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Suboxone market share has declined with the at-risk launch of Dr. Reddy’s generic competitor, while Indivior awaits a court decision on a requested temporary restraining order against the launch.
- Drug Discovery Tools
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- KemPharm Inc.
- Senior Management
Travis C Mickle, PhD, Pres., CEO & Chmn.
R. LaDuane Clifton, CFO, Secretary & Treasurer
Christopher Lauderback, PhD, VP, Manufacturing
Sven Guenther, PhD, EVP, R&D
Gordon "Rusty" K Johnson, CBO
Rene A Braeckman, PhD, VP, Clinical Dev.
- Contact Info
Phone: (319) 665-2575
1180 Celebration Blvd.
Celebration, FL 34747
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.